3,5-Bicyclic aryl piperidines: A novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation

https://doi.org/10.1016/j.bmcl.2005.08.035Get rights and content

Abstract

3,5-Bicyclic aryl piperidines are a new class of high-affinity α4β2 nicotinic receptor agents. We have sought nicotinic receptor partial agonists of the α4β2 nicotinic acetylcholine receptor for smoking cessation, and a number of compounds fulfill potency, selectivity, and efficacy requirements in vitro. In vivo, selected agents demonstrate potent partial agonist efficacy on the mesolimbic dopamine system, a key measure of therapeutic potential for smoking cessation.

References and notes (51)

  • L.E. Chavez-Noriega et al.

    Neuropharmacology

    (2000)
    M.E. Nelson et al.

    Mol. Pharmacol.

    (2003)
  • R.C. Hogg et al.

    Curr. Drug. Targets CNS Neuro. Disord.

    (2004)
  • R.S. Mansbach et al.

    Psychopharmacology

    (2000)
  • M.C. Fiore et al.

    Treating tobacco use and dependence: Clinical practice guideline

    (2000)
  • J.E. Rose

    Annu. Rev. Med.

    (1996)
  • S.H. de Villiers et al.

    Respiration

    (2002)
    N. Lindblom et al.

    Respiration

    (2002)
  • J.W. Coe

    Org. Lett.

    (2000)
    B.T. O’Neill et al.

    Org. Lett.

    (2000)
  • E.H. Huntress et al.

    J. Am. Chem. Soc.

    (1941)
  • Vogel’s Textbook of Practical Organic Chemistry, 5th ed; Wiley: New York, 1989; pp...
  • H.O. House et al.

    J. Org. Chem.

    (1969)
  • K.N. Campbell et al.

    J. Am. Chem. Soc.

    (1945)
  • (a)World Health Organization. Geneva,...R. Doll et al.

    BMJ

    (2004)
  • J.A. Dani et al.

    Pharmacol. Biochem. Behav.

    (2001)
  • M.R. Picciotto et al.

    Nature

    (1998)
    S.S. Watkins et al.

    Pharmacol. Biochem. Behav.

    (1999)
    C. Cohen et al.

    J. Pharmacol. Exp. Ther.

    (2003)
  • A.R. Tapper et al.

    Science

    (2004)
  • U. Maskos et al.

    Nature

    (2005)
  • G. Di Chiara

    Eur. J. Pharmacol.

    (2000)
    J.A. Dani et al.

    Pharmacol. Biochem. Behav.

    (2001)
  • K. Fagerstrom

    J. Clin. Psychiatry. Monograph.

    (2003)
  • J.R. Hughes et al.

    Addiction

    (1994)
    D.H. Malin

    Pharmacol. Biochem. Behav.

    (2001)
  • J.R. DiFranza et al.

    J. Nic. Tobacco Res.

    (2005)
    M.W. Quick et al.

    J. Neurobiol.

    (2002)
    J. Littleton

    Addiction

    (2001)
  • J.T. Hays et al.

    Mayo Clin. Proc.

    (2003)
  • K.J. Holm et al.

    Drugs

    (2000)
  • J.F. Cryan et al.

    Drug Disc. Today

    (2003)
  • J.A. Lieberman

    CNS Drugs

    (2004)
    B.T. Zhu

    J. Theor. Biol.

    (1996)
  • J.W. Coe et al.

    Bioorg. Med. Chem. Lett.

    (2005)
  • Cited by (62)

    • Merging metals and strained intermediates

      2022, Chem Catalysis
      Citation Excerpt :

      Now, 120 years later, the existence of cyclic alkynes and related species is widely accepted.2–17 The strain associated with these species can be leveraged strategically to access a number of important compounds, including ligands,18 fungicides,19 medicinal agents,20 and natural products.4,5,17,21,22 To pay tribute to key historical advances and highlight two major modes of strained intermediate reactivity, we feature pioneering studies from the 1950s and 1960s.

    • ADHD symptoms impact smoking outcomes and withdrawal in response to Varenicline treatment for smoking cessation

      2017, Drug and Alcohol Dependence
      Citation Excerpt :

      Regarding smoking cessation, varenicline is a first-line treatment, with some head-to-head studies suggesting that varenicline may be more effective than other first line medications such as nicotine replacement and bupropion (Aubin et al., 2008; Gonzales et al., 2006; Nides et al., 2006) and others suggesting it is similarly effective to nicotine replacement therapies (Baker et al., 2016). Preclinical studies indicate that varenicline acts as a partial agonist at the α4β2 nicotinic acetylcholine receptor (nAChR), with both agonist and antagonist effects (Coe et al., 2005; Rollema et al., 2007). Varenicline is thought to reduce craving and attenuate withdrawal, restlessness, and negative affect during abstinence, potentially via its antagonist action at α4β2 nAChRs, which play a role in mediating nicotine reinforcement (Aubin et al., 2008; Stapleton et al., 2008).

    • Agonist and antagonist effects of cytisine in vivo

      2015, Neuropharmacology
      Citation Excerpt :

      Taking into account poor plasma protein binding (Rollema et al., 2010) and brain/plasma concentration ratio of about 0.3 (Reavill et al., 1990) and assuming that brain protein binding is not much different from plasma protein binding, one may estimate that behaviorally effective doses of cytisine are associated with free brain concentrations of 0.2–0.8 μM (0.7 μM after oral administration of 10 mg/kg of cytisine; Rollema et al., 2010). Given that cytisine binding Ki for α4β2* nicotinic receptors was reported to be in low nanomolar range (Coe et al., 2005; Rollema et al., 2010), such estimates trigger a question whether effects of cytisine are indeed mediated by α4β2 subunit-containing nicotinic receptors. However, one should note that cytisine is a very weak agonist at α4β2* receptors and, in functional assays, cytisine's potency is in micromolar range (Rollema et al., 2010).

    View all citing articles on Scopus
    View full text